Have Insiders Been Buying OncoSil Medical Limited (ASX:OSL) Shares This Year?

It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So shareholders might well want to know whether insiders have been buying or selling shares in OncoSil Medical Limited (ASX:OSL).

What Is Insider Selling?

Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock in the company. However, such insiders must disclose their trading activities, and not trade on inside information.

We would never suggest that investors should base their decisions solely on what the directors of a company have been doing. But logic dictates you should pay some attention to whether insiders are buying or selling shares. As Peter Lynch said, ‘insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

See our latest analysis for OncoSil Medical

The Last 12 Months Of Insider Transactions At OncoSil Medical

Over the last year, we can see that the biggest insider purchase was by Non-Executive Director Roger Aston for AU$102k worth of shares, at about AU$0.09 per share. We do like to see buying, but this purchase was made at well below the current price of AU$0.12. Because the shares were purchased at a lower price, this particular buy doesn’t tell us much about how insiders feel about the current share price.

OncoSil Medical insiders may have bought shares in the last year, but they didn’t sell any. You can see the insider transactions (by individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

ASX:OSL Recent Insider Trading June 17th 2020
ASX:OSL Recent Insider Trading June 17th 2020

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insiders at OncoSil Medical Have Bought Stock Recently

It’s good to see that OncoSil Medical insiders have made notable investments in the company’s shares. In total, insiders bought AU$228k worth of shares in that time, and we didn’t record any sales whatsoever. This is a positive in our book as it implies some confidence.

Does OncoSil Medical Boast High Insider Ownership?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it’s a good sign if insiders own a significant number of shares in the company. Insiders own 13% of OncoSil Medical shares, worth about AU$13m, according to our data. Overall, this level of ownership isn’t that impressive, but it’s certainly better than nothing!

So What Does This Data Suggest About OncoSil Medical Insiders?

It’s certainly positive to see the recent insider purchases. And an analysis of the transactions over the last year also gives us confidence. However, we note that the company didn’t make a profit over the last twelve months, which makes us cautious. When combined with notable insider ownership, these factors suggest OncoSil Medical insiders are well aligned, and that they may think the share price is too low. So while it’s helpful to know what insiders are doing in terms of buying or selling, it’s also helpful to know the risks that a particular company is facing. For example, OncoSil Medical has 5 warning signs (and 1 which is concerning) we think you should know about.

But note: OncoSil Medical may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Love or hate this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Thank you for reading.